Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART

Stopped Slow recruitment therefore study was stopped after 95% volunteers were enrolled.

Conditions

• HIV-1

Interventions

• BIOLOGICAL: MVA.HIVconsv low dose
• OTHER: Placebo low dose
• BIOLOGICAL: MVA.HIVconsv high dose
• OTHER: Placebo high dose

Sponsor

University of Oxford

Collaborators

• [object Object]